Search results
Results from the WOW.Com Content Network
[223] [224] In 1954, the stimulant methylphenidate (Ritalin, which was first produced in 1944) became available; it remains one of the most widely prescribed medications for ADHD. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ...
The most comprehensive meta-analysis available (19 studies with over 3.9 million participants) found "no statistically significant association between ADHD medications [including methylphenidate] and the risk of cardiovascular event among children and adolescents, young and middle-aged adults, or older adults"; [44] as do other systematic ...
The side effects vary widely among individuals but most commonly include insomnia, dry mouth, loss of appetite and weight loss. The risk of developing an addiction or dependence is insignificant when Adderall is used as prescribed and at fairly low daily doses, such as those used for treating ADHD.
Millions of children and adults in the United States are prescribed medications to treat ADHD, a neurological disorder which causes differences in the brain that affect executive functioning.
A meta-analysis of the global prevalence of ADHD in adults, published in 2021, estimated a collective prevalence of persistent adult ADHD of 2.58% globally in 2020. [4] Persistent adult ADHD is defined as meeting diagnostic criteria for ADHD in adulthood with the additional requirement of a confirmed childhood diagnosis. [4]
But even with a prescription, a recent CDC report shows nearly three quarters of ADHD patients prescribed stimulant drugs are reporting difficulty getting the medications due to ongoing shortages.
ADHD prescription rates have historically been lower for women than men ... (an ADHD medication marketed under brand names like Ritalin and Concerta) than boys (55.8% vs. 69.7%, respectively ...
Other side effects, such as tics, decreased appetite and weight loss, or emotional lability, may also lead to discontinuation. [237] Stimulant psychosis and mania are rare at therapeutic doses, appearing to occur in approximately 0.1% of individuals, within the first several weeks after starting amphetamine therapy.